| Project/Area Number |
16H05466
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Kindai University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
吉村 一宏 近畿大学, 医学部, 教授 (20283757)
デベラスコ マルコ 近畿大学, 医学部, 助教 (20449838)
原田 守 島根大学, 学術研究院医学・看護学系, 教授 (50260716)
南 高文 近畿大学, 医学部, 講師 (70340809)
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥17,290,000 (Direct Cost: ¥13,300,000、Indirect Cost: ¥3,990,000)
Fiscal Year 2018: ¥7,020,000 (Direct Cost: ¥5,400,000、Indirect Cost: ¥1,620,000)
Fiscal Year 2017: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
|
|---|
| Keywords | 腎細胞癌 / がんワクチン / ペプチドワクチン / 免疫療法 / HLA-A2 |
|---|
| Outline of Final Research Achievements |
We have been working on the development of new MHC-class-I restricted peptide vaccines for five independent therapeutic targets （CA9、VEGFR1、EPOR、PDL1、HIF1）and have identified a significant candidate a part of HLA-A2 restricted peptide vaccines (EPOR, PDL1 and HIF1). We are currently investigating their clinical relevance. Together with CA9 and VEGFR1 previously developed peptide vaccines, we will establish multi-peptide vaccination system using these five peptide vaccines.
|
| Academic Significance and Societal Importance of the Research Achievements |
昨今、免疫チェックポイント阻害薬の登場により、がん免疫療法の有用性が再認識されている。近い将来、癌治療は単一療法から複合免疫療法の時代へと移りつつあり、このような現状を鑑みると本研究のような新規ワクチン療法の開発は重要な課題と思われる。
|
